JP7163180B2 - ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用 - Google Patents

３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用 Download PDF

Info

Publication number
JP7163180B2
JP7163180B2 JP2018515622A JP2018515622A JP7163180B2 JP 7163180 B2 JP7163180 B2 JP 7163180B2 JP 2018515622 A JP2018515622 A JP 2018515622A JP 2018515622 A JP2018515622 A JP 2018515622A JP 7163180 B2 JP7163180 B2 JP 7163180B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
independently
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018515622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535930A5 (https=
JP2018535930A (ja
Inventor
ガーマン，ティモシー
シャウ，アンドリュー
コロドナー，リチャード
Original Assignee
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルードヴィッヒ インスティテュート フォー キャンサー リサーチ・リミテツド filed Critical ルードヴィッヒ インスティテュート フォー キャンサー リサーチ・リミテツド
Publication of JP2018535930A publication Critical patent/JP2018535930A/ja
Publication of JP2018535930A5 publication Critical patent/JP2018535930A5/ja
Application granted granted Critical
Publication of JP7163180B2 publication Critical patent/JP7163180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2018515622A 2015-09-25 2016-09-26 ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用 Active JP7163180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233110P 2015-09-25 2015-09-25
US62/233,110 2015-09-25
PCT/IB2016/001473 WO2017051251A1 (en) 2015-09-25 2016-09-26 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators

Publications (3)

Publication Number Publication Date
JP2018535930A JP2018535930A (ja) 2018-12-06
JP2018535930A5 JP2018535930A5 (https=) 2020-07-09
JP7163180B2 true JP7163180B2 (ja) 2022-10-31

Family

ID=57256366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515622A Active JP7163180B2 (ja) 2015-09-25 2016-09-26 ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用

Country Status (7)

Country Link
US (1) US11253521B2 (https=)
EP (1) EP3353154B3 (https=)
JP (1) JP7163180B2 (https=)
CN (1) CN108430978B (https=)
AU (1) AU2016325601C1 (https=)
CA (1) CA2998294C (https=)
WO (1) WO2017051251A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202113610D0 (en) 2021-09-23 2021-11-10 Francis Crick Institute Ltd Novel method
CN114539148A (zh) * 2022-01-25 2022-05-27 北京英飞智药科技有限公司 一种环状n-羟基酰亚胺类化合物及其用途
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法
WO2023219958A2 (en) * 2022-05-09 2023-11-16 The Regents Of The University Of California Methods for the treatment of nlrp3 related disorders
WO2025172707A1 (en) * 2024-02-13 2025-08-21 Merck Patent Gmbh Heterocyclic compounds modulating exonuclease 1 (exo1)
WO2025172706A1 (en) * 2024-02-13 2025-08-21 Merck Patent Gmbh Compounds modulating flap endonuclease (fen1)
EP4686475A1 (en) 2024-07-31 2026-02-04 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Xpg inhibitors for use in the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CS266762B1 (cs) * 1988-06-15 1990-01-12 Pazdera Pavel 3-Subst.ituované 4-lmlno-l ,2,3,4-tetrano-l ,2,3,4-tetra-hydrochlnazolin-2-thiony a způsob jejich přípravy
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
DK1028950T3 (da) * 1997-10-28 2003-09-01 Warner Lambert Co 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler
WO2001070737A2 (en) * 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
WO2012047993A2 (en) * 2010-10-05 2012-04-12 Regents Of The University Of Minnesota N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv
CN105669653B (zh) 2016-03-14 2018-08-21 山东大学 一种n-羟基杂环并嘧啶二酮类衍生物及其制备方法与应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS REGISTRY NO. 1305710-47-7，DATABASE REGISTRY, [online]，2011年06月06日，[2020.06.18検索], Retrieved from: STN
Ghoneim, K. M. 他，Novel 2-substituted aminonicotinhydroxamic acids，Egyptian Journal of Pharmaceutical Sciences ，1987年，28(1-4)，9-16，CA 108:204459
GHONEIM, KM et al.，Novel 2-Substituted Aminonicotinhydroxamic Acids，Egyptian Journal of Pharmaceutical Sciences ，1987年，Vol. 28，pp. 9-16
REGISTRY（STN）[online]，2011.06.05[検索日 2020.06.18]CAS登録番号 1305710-47-7
TSERNG, K et al.，3-Hydroxypyridopyrimidine-2,4(1H,3H)diones，Journal of Heterocyclic Chemistry，1972年，Vol. 9，pp. 1433-1435
Tserng, Kou-Yi 他，3-Hydroxypyridopyrimidine-2,4(1H,3H)-diones，Journal of Heterocyclic Chemistry，1972年，9(6)，1433-1435

Also Published As

Publication number Publication date
US20200237763A1 (en) 2020-07-30
CA2998294C (en) 2023-09-12
AU2016325601C1 (en) 2022-03-31
CN108430978A (zh) 2018-08-21
CA2998294A1 (en) 2017-03-30
EP3353154B3 (en) 2022-10-19
WO2017051251A1 (en) 2017-03-30
CN108430978B (zh) 2022-11-22
US11253521B2 (en) 2022-02-22
AU2016325601B2 (en) 2021-04-15
AU2016325601A1 (en) 2018-03-29
JP2018535930A (ja) 2018-12-06
EP3353154B1 (en) 2020-08-19
EP3353154A1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
JP7163180B2 (ja) ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用
CN107207474B (zh) 被取代的杂环作为溴结构域抑制剂
ES2676826T3 (es) Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos
CN105308036B (zh) 用于激酶调节的化合物和方法及其适应症
CN109071455B (zh) 用于调节布鲁顿酪氨酸激酶的化合物及方法
JP2015532287A (ja) Ｉｒｅ１の調節
US20160046616A1 (en) Nrf2 small molecule inhibitors for cancer therapy
CA2915622A1 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
WO2017044889A1 (en) Lrh-1 modulators
CA2966303A1 (en) Substituted pyridines as bromodomain inhibitors
CN114585625A (zh) 作为a2a/a2b抑制剂的三唑并嘧啶
TWI748996B (zh) 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用
JP2024160326A (ja) Ｅａａｔ２活性化因子およびその使用方法
CA3067695A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3399976A1 (en) Benzothiazole amphiphiles
CN101484457A (zh) 作为用于治疗增殖病症的蛋白激酶PLK1抑制剂的4,5-二氢-[1,2,4]三唑并[4,3-f]蝶啶
CN112237579A (zh) 药物组合及其用途
US11117894B2 (en) Pyridopyrazine compounds and uses thereof
WO2025166286A1 (en) Compositions and methods for treating cancer and reducing wnt mediated effects
HK40035225A (en) Pharmaceutical combination and use thereof
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220707

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220905

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221019

R150 Certificate of patent or registration of utility model

Ref document number: 7163180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150